Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci192804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Jingxi Mu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology. Hauptthemen laut MEDLINE: Fibroblasts, Inflammatory Bowel Diseases, Intestines, Crohn Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Dysfunctional intestinal fibrosis is an irreversible complication of Crohn’s disease (CD). The complex heterogeneity of intestinal mesenchymal cells makes it difficult to understand the pathogenesis of intestinal fibrosis. Previously, we identified Meflin as a marker of fibroblast subsets. This study aimed to explore the role of Meflin-positive fibroblasts in intestinal fibrogenesis and investigate the potential of pharmacological control of Meflin expression as a treatment for patients with CD. Our results indicated that Meflin expression was upregulated in fibroblasts at the early stage of fibrosis but was downregulated in established fibrosis in both patients with CD and 2 different mouse models, which are the chronic dextran sodium sulfate (DSS) model and an IL-10–deficient model that spontaneously develops intestinal inflammation. Meflin-deficient mice exacerbated intestinal fibrosis with dysregulated expression of noncanonical Wnt ligand WNT5A and its receptor ROR2. Pharmacologically induced Meflin expression through the administration of a synthetic retinoid reversed intestinal fibrosis in the DSS model and suppressed profibrotic protein secretion in fibroblasts isolated from patients with CD. Our findings indicate that Meflin-positive fibroblasts represent a functional subpopulation that suppresses intestinal fibrosis. Augmentation of Meflin expression shows antifibrotic effects and holds promise as a therapeutic approach for intestinal fibrosis in patients with CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology.
- Department of Pathology.
- Department of Endoscopy.
- Department of Immunology, and.
- Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Förderung
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
- JSIBD Grants-in-Aid for IBD Research
Zitieren
APA
Mu, J., Maeda, K., Iida, T., Mii, S., Esaki, N., Shiraki, Y., Mizutani, Y., Nakamura, M., Yamamura, T., Sawada, T., Ishikawa, E., Murate, K., Hirose, T., Furukawa, K., Oishi, A., Suzuki, H., Kishida, T., Nakayama, G., Fujishiro, M., …, & Enomoto, A. (2026). Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci192804
Vancouver
Mu J, Maeda K, Iida T, Mii S, Esaki N, Shiraki Y, et al. Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease. Journal of Clinical Investigation. 2026. doi:10.1172/jci192804
BibTeX
@article{Mu2026,
author = {Mu, Jingxi and Maeda, Keiko and Iida, Tadashi and Mii, Shinji and Esaki, Nobutoshi and Shiraki, Yukihiro and Mizutani, Yasuyuki and Nakamura, Masanao and Yamamura, Takeshi and Sawada, Tsunaki and Ishikawa, Eri and Murate, Kentaro and Hirose, Takashi and Furukawa, Kazuhiro and Oishi, Akina and Suzuki, Haruhiko and Kishida, Takayoshi and Nakayama, Goro and Fujishiro, Mitsuhiro and Kawashima, Hiroki and Enomoto, Atsushi},
title = {Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci192804}
}
EUVIMED